Biocytogen to Highlight Bispecific ADC Pipeline at World ADC London 2023
Biocytogen is excited to attend and deliver oral and poster presentations at the upcoming 13th World ADC London conference, held on March 13th-16th, 2023. Dr.…
Read moreBiocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008
BEIJING, China, February 27, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co.,…
Read moreBiocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets
BEIJING, China, February 21, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims…
Read moreWebinar: Inflammatory Disease Modeling for Preclinical Studies
Our webinar “Inflammatory Disease Modeling for Preclinical Studies" was live at 1:00 PM EST on February 15th, 2023. In this webinar, we Provided a brief overview…
Read morePepTalk 2023
Join us at booth #401 at PepTalk 2023 from January 16-20 in San Diego, CA! Whether you need humanized models, PK/PD services, or antibody discovery…
Read moreBiocytogen and Hansoh Pharma Announce an Antibody License Agreement
BEIJING, China, and Shanghai, China, January 3, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus…
Read moreBiocytogen Launches RenNano® Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery
Beijing, China, December 30, 2022 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today officially launched its fully human heavy chain antibody platform, RenNano®. RenNano® is the…
Read more7th Tumor Models for Immuno-Oncology Summit
Join us at the 7th Tumor Models for Immuno-Oncology Summit in San Francisco, CA from January 24 - 26, 2023! We will be presenting "Next-Generation…
Read moreBiocytogen BDL Team to Participate in the 41st Annual JPM Healthcare Conference, the Biotech Showcase and BIO Partnering at JPM
Biocytogen (HKEX: 02315) will attend the upcoming 41st J.P. Morgan (JPM) Healthcare Conference week, and participate in several satellite conferences, including the Biotech Showcase and…
Read moreBiocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008
BEIJING, China, December 19, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that the US FDA has approved the Investigational New…
Read more